CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 1The	safety	of	Boostrix
following	routine	immunization	
of	pregnant	women
EPI-PERTUSSIS -047	VS	US	DB (207221)
Final Version of December 15, 2017
Amendm ent 1 ‚ÄìNovem ber 13, 2018
Amendm ent 2 ‚ÄìNovem ber 12, 2019
Sponsor: GlaxoSmithKline Biologicals SA
Rue de l‚ÄôInstitut 89
1330
Rixensart, Belgium
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a1 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 2Protocol Amendment 2Sponsor Signatory  Approval
eTrack study number and 
Abbreviated Title207221 ( EPI-PERTUSSIS -047 VS US DB )
Date of protocol Final: 15 D ecember 2017
Date of protocol amendment 1 Final: 13 November 2018
Date of protocol amendment 2 Final: 12 November 2019
Detailed Title An observational, retrospective cohort database 
study  to assess the safet y of Boostrix (U.S. 
formulation), a reduced tetanus, diphtheria, 
acellular pertussis vaccine (Tdap), following 
routine immunization of pregnant women in the 
United States. 
Sponsor signatory Nadia Meyer, MD
Clinical and Epidemiology  R&D Project Leader 
(CEPL ), DTP, Polio, Hib containing vaccines
GSK Biologicals‚Äô R&D Center Belgium
Signature
Date
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a2 12-NOV-2019 For internal use only
 - ----------------Checksum----------------!Ver.!Created On -  - 
05cc3b67a9ba431ae514559e26df5e5186fbe84a 2.0 11/18/2019 10:52:23 AM 
-  - ---------------------------------------------------------------------------- - 
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 3Protocol A mendment 1 Rationale
Amendment number: Amendment 1
Rationale/background for changes:
The protocol has been amended following the comments received from the Center for 
Biologics Evaluation and Research . The following changes were implement ed:
ÔÇ∑Objectives: The protocol has been modified to include pregnancies irrespective of
low or high -risk status (to reflect the current use of the vaccine) .A primary
objective has been added to rule out a two-fold increase in the incidence of four
pre-specified maternal and infant adverse events. A secondary  objective has been
added to explore differences in eight other pre -specified maternal and infant
adverse events.
ÔÇ∑Endpoints:
ÔÄ≠The list of endpoints has been reviewed in view of their medical and scientific
significance . Prioritization of endpoints was also based on the 2014
collaboration between the Brighton Collaboration Foundation and the World
Health Organization (WHO) toaddress gaps in the safet y assessment of
vaccines 
during pregnancy (1). The following endpoints were removed:
Gestational diabetes, premature uterine contractions, macrosomia, fetal
distress, placenta previa, and delivery  methods. The following endpoints were
added: S mall for gestational age(SGA) , preterm delivery , neonatal d eath,
maternal death, and p reterm pre -labor rupture of membranes (PPROM
).
ÔÄ≠Spontaneous abortion with or without congenital anomaly  (CA) and
therapeutic abortion with or without CAoccur ,bydefinition ,before 2 0weeks
of gestation (2). Therefore, these events will not be part of the mai n anal ysis
on the safet y of Boostrix administered after the 27th week of gestation.
However, the incidence of these events will be collected for subjects who
received Boostrix prior to the 27th week of gestation and described in the
study  report.
ÔÄ≠Endpoints have been classified as either primary  or secondary .
ÔÇ∑Risk factors : additional factors defining a pregnancy  as ‚Äúhigh- risk‚Äù ha vebeen
added.
ÔÇ∑Case definitions: P re- specified maternal and infant adverse events reflect the data
captured b y ICD-9 and ICD- 10 coding according to the clinical practice of
obstetrics.
ÔÇ∑Further details on the statistical methods have been added for each endpoint.
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a3 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 4Protocol Amendment 2 Rationale
Amendment number:  Amendment 2
Rationale/background for changes:
The protocol has been amended to modify the secondary endpoint of ‚Äúpost -
partum hemorrhage (PPH)‚Äù to ‚Äútransfusion during delivery hospitalization‚Äù as 
a proxy for severe PPH. We originally planned to identify PPH from automated 
diagnosis codes (ICD -9 and ICD -10) and then perform chart review to confirm 
the event. However, in October 2017 (ACOG Practice Bulletin PPH 2017), the 
threshold for estimated blood loss (EBL) for PPH diagnosis changed, affecting 
the comparison between the historical (~2012- 2013) and th e Boostrix exposed 
(2018 -2019) cohorts. The potential for using EBL as an objective measure is 
limited by differential missingness of EBL data between these two cohorts as well 
as inconsistency in EBL measurements. We propose to use transfusion during 
delivery hospitalization as an indicator of severe blood loss and as a proxy for 
severe PPH. Transfusion can be captured by procedure codes, and transfusion 
data are stable across the study period. Transfusion is a relevant endpoint 
because hemorrhage that lea ds to blood transfusion is the leading cause of severe 
maternal morbidity in the United States (ACOG Practice Bulletin PPH 2017).
The following changes have been implemented .
ÔÇ∑Secondary objectives; Data collection Figure 1; Statistical methods Tables 6 and
7 -"Post -partum hemorrhage" was changed to "Transfusion during delivery
hospitalization."
ÔÇ∑Case definitions; Data collection and management -Transfusion during delivery
hospitalization is captured by procedure codes and will not be chart reviewed.
ÔÇ∑Data collection Figure 1; Statistical methods Table 7 - Transfusion will be
identified among pregnant women with delivery hospitalizations.
ÔÇ∑Analysis of primary and secondary objectives; Statistical methods Table 7 
-The
statistical method for analyzing transfus ion will be an adjusted Poisson
regression model. Robust variance estimation is not planned since the incidence
is expected to be <2%.
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a4 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 5Protocol Amendment 2Investigator Agreement
I agree:
ÔÇ∑To conduct the stud y in compliance with this protocol, an y mutually agreed future
protocol amendments or protocol administrative changes, with the terms of the study
agreement and with an y other mutually agreed upon study  conduct procedures and/or
study  conduct documents provided by  GlaxoSmithKline Biologicals (GSK
Biolog icals).
ÔÇ∑To assume responsibility for the proper conduct of the study .
ÔÇ∑That I am aware of, and will comply  with applicable guidelines and all applicable
regulatory  requirements, such as the Declaration of Helsinki, International Ethical
Guidelines for Epide miological Studies ( Council for International Organizations of
Medical Sciences [ CIOMS] ), United States Food and Drug Administration (FDA)
Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies
using Electronic Healthcare Data, and International Society  for
Pharmacoepidemiology (ISPE ) guidelines for Good Pharmacovigilance Practice
(GPP) .
ÔÇ∑To ensure that all persons assisting me with the study  are adequatel y informed about
study -related duties and functions as described in the protoc ol.
ÔÇ∑That I have been informed that certain regulatory  authorities require the sponsor to
obtain and supply , as necessary , details about the investigator‚Äôs ownership interest in
the sponsor, and more generall y about his/her financial ties with the sponsor. GSK
Biologicals will use and disclose the information solely  for the purpose of comply ing
with regulatory  requirements.
Hence I:
ÔÇ∑Agree to suppl y GSK Biologicals with an y necessary  information regarding
ownership interest and financial ties (including those of my  spouse and dependent
children).
ÔÇ∑Agree to promptl y update this information if an y relevant changes occur during the
course of the stud y and for one year following completion of the study.
ÔÇ∑Agree that GSK Biologicals may  disclose any  information it has about such
ownership interests and financial ties to regulatory authorities.
ÔÇ∑Agree to provide GSK Biologicals with an updated Curriculum Vitae and other
documents required b y regulatory  agencies for this study , within reason .
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a5 12-NOV-2019
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
12-NOV-2019 6eTrack study number and
Abbreviated Title207221 (EPI-PERTUSSIS-047 VS US DB)
Date of protocol Final: 15 December 2017
Date of protocol amendment 1 Final: 13 November 2018
Date of protocol amendment 2 Final: 12 November 2019
Detailed Title An observational, retrospective cohort database 
study to assess the safety of Boostrix (U.S.formulation), a reduced tetanus, diphtheria, acellular pertussis vaccine (Tdap), following routine immunization of pregnant women in the United States. 
Principal Investigator name Hung Fu Tseng, PhD, MPH
Research Scientist III
Kaiser Permanente Southern CaliforniaDepartment of Research and Evaluation
Tel: 
Fax: Email:
Signature
Date
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a6 12-NOV-2019)RULQWHUQDOXVHRQO\
&KHFNVXP9HU&UHDWHG2Q 
FFEDEDDHHGIHIEHD $0
 PPD
PPD
PPD
PPD
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 7SYNOPSIS
Detailed Title An observational, retrospective cohort database study  to 
assess the safety  of Boostrix (U.S.formulation) , a reduced 
tetanus ,
diphtheria, acellular pertussis vaccine ( Tdap ),
following routine immunization of pregnant women in the 
United States.
Rationale for the 
studyTo describe the safet y of Boostrix administered during 
pregnancy  by conducting a post -marketing stud y that will 
provide safet y information to the public and healthcare 
providers. This will be one of the largest cohorts of pregnant 
women vaccinated with Boostrix in the U.S. Through 
partnership 
between Ka iser Permanente Southern California 
(KPSC) and the sponsor, GlaxoSmithKline (GSK), we will 
provide information about the safet y of maternal vaccination 
with Boostrix and maternal and infant adverse events in a 
community  setting.
Primary  endpoints were differentiated from secondary  
endpoints to allow evaluating the safet y ofmaternal 
vaccination with sufficient statistical power on the primary  
endpoints and to allow for hypothesis generation/signal 
detection on secondary  endpoints.
Primary  endpoints were selected based on their medical 
relevance , also considering the background incidence or 
prevalence of these endpoints .
Description of the 
databaseVaccination and medical event data will be extracted directl y 
from the electronic healthrecord (
EHR, Health Connect), 
which is the legal record of all medical care received within 
the 
KPSC health care system. Records of vaccinations and 
medical events can onl y be entered b y medical staff .
Primary Objective To rule out a two- fold increase (non-inferiorit ytesting) in the 
incidence of
each of the following maternal and infant adverse 
events :
ÔÇ∑Preeclampsia and/or eclampsia
ÔÇ∑Intra -uterine infections such as chorioamnionitis and
endometritis
ÔÇ∑Small for gestational age (SGA)
ÔÇ∑Preterm delivery
among women who were vaccinated with Boostrix on or after 
the 1stday of the 27thweek of gestation as compared to the 
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a7 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 8incidence in ahistorical cohort of pregnant women 
(approximately  January  1, 2012 to December 31, 2013) who 
were unvaccinated with any  Tdap vaccine throu
ghout their 
pregnancy .
Secondary 
Objective s
(amended 12
November 2019)1.
To explore the difference (superiorit ytesting) in the 
incidence rate of other maternal and infant adverse 
events, namel y:
ÔÇ∑Transfusion during delivery hospitalization (as a proxy 
for severe post -partum hemorrhage)
ÔÇ∑Poor fetal growth
ÔÇ∑Stillbirth/fetal death with or without congenital anomalies
ÔÇ∑Neonatal death (within 28 day s of birth)
ÔÇ∑Maternal death (while pregnant or within 42 day s of end 
of pregnancy ) 
ÔÇ∑Placental abruption
ÔÇ∑Preterm pre -labor rupture of membranes (PPROM)
ÔÇ∑Congenital anomalies (CA) at birth and through 6 months 
of age
between women who were vaccinated with Boostrix on or 
after the 1stday of the 27thweek of gestation and a 
historical cohort of pregnant women ( approximately  
January  1, 2012 to December 31, 2013) who were 
unvaccinated with an y Tdap vaccine throughout their 
pregnancy .
2.To describe the incidence of maternal and infant adverse 
events described above, as well as the incidence of 
spontaneous and therapeutic abor tionswith or without 
congenital anomalies , among pregnant women vaccinated 
with Boostrix before the 27thweek of gestation
. 
Study design ÔÇ∑Type of study : Observational retrospective database study
ÔÇ∑Type of design: Matched cohort study
ÔÇ∑End of study : The date the database anal ysis is 
completed.
ÔÇ∑Primary  completion date: The date of final collection of
data for all outcomes
ÔÇ∑Study  population: pregnant women with prenatal care and 
continuous membership (allowing up to a 31 -day gap) at 
KPSC between the 1stday of the 27thweek of pregnancy  
and the index (vaccination) date
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a8 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 9ÔÄ≠Exposed (from the 27th week of gestation) :Wome n 
who received the Tdap vaccine (Boostrix) on or after 
the 1stday of the 27thweek of pregnancy ; and who 
were not vaccinated with any other Tdap v accine at 
any other time during 
the pregnancy  in scope of this 
study .
ÔÄ≠Unexposed: Women matched to the exposed cohort, 
pregnant sometime durin g the approximate estimated 
period between 1/1/2012 -12/31/2013 who did not 
receive an y Tdap vaccine during the pregnancy  in 
scope of this study .
Of note, women vaccinated with Boostrix before the 27th
week of gestation, with membership at the date of vaccination, 
and who were not vaccinated with an y other Tdap vaccine at 
any other time during the pregnancy  in scope of this study  will 
be part of a descriptive analy sis (secondary  objective).
ÔÇ∑General stud y aspects: Subject -level data will be 
collected for pregnant women and their infants through 
the EHR. For each individual pregnant woman, follow up 
will begin on the date they received the Boostrix vaccine, 
or the index date for the unvaccinated cohort, an d will 
end on the date of disenrollment or the end of pregnancy , 
whichever came first. Infants born in KPSC hospitals 
from unvaccinated and vaccinated mothers will be 
followed for 6 months.
Number of subjects Approximately  15,000 pregnant women vaccinated with 
Boostrix over a period of approximately  one year. 
Unexposed pregnant women will be matched 1:1 to the 
exposed group and will be identified from a historical cohort. 
We aim to have a total sample size of approximately  30,000 
pregnant women. 
Endpoin t(s)
(amended 12
November 2019)Primary
Maternal and infant adverse events identified from KPSC‚Äôs 
EHR sy stem using the pregnancy  episode flowsheet and
diagnosis codes
:
ÔÇ∑Preeclampsia and eclampsia 
ÔÇ∑Intra -uterine infections such as chorioamnionitis and
endometritis 
ÔÇ∑Small for gestational age (SGA)
ÔÇ∑Preterm delivery
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a9 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 10Secondary
Maternal and infant adverse events identified from KPSC‚Äôs 
EHR sy stem using the pregnancy  episode flowsheet, diagnosis 
codes, procedure codes, or death records:
ÔÇ∑Transfusion during delivery hospitalization
ÔÇ∑Poor fetal growth
ÔÇ∑Stillbirth/fetal death with or without congenital anomalies
ÔÇ∑Neonatal death (within 28 day s of birth)
ÔÇ∑Maternal death (while pregnant or within 42 day s of end 
of pregnancy ) 
ÔÇ∑Placental abruption
ÔÇ∑Preterm pre -labor rupture of membranes (PPROM)
ÔÇ∑Congenital anomalies (CA) at birth and through 6 months 
of age overall and b y system organ class
ÔÇ∑Spontaneous abortion (only  for women exposed to 
Boostrix before the 27thweek of gestation)
ÔÇ∑Therapeutic abortion (only  for women exposed to 
Boostrix before the 27thweek of gestation)
To avoid capture of preexisting conditions, diagnostic codes 
representing each condition should not appear prior to the 
index date within the pregnancy  under stud y.With the 
exception of SGA , preterm delivery ,and transfusion , medical 
records of the potential events will then be reviewed by 
trained research associates to confirm the diagnosis and to 
ascertain that it is an incident event. Anal yses will be done on 
chart confirmed incident events.
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a10 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 F inal
12-NOV -2019 11TABLE OF CONTENTS
PAGE
SYNOPSIS ................................ ................................
...................................................... 7
LIST OF ABBREVIATION S........................................................................................... 14
GLOSSARY OF TERMS ............................................................................................... 16
1.INTRODUCTION .................................................................................................... 18
1.1. Background ................................................................................................ 18
1.2. Rationale for the study ................................................................................ 19
2.OBJECTIVE ........................................................................................................... 20
2.1. Primary objective ........................................................................................ 20
2.2. Secondary objectives (amended 12 November 2019) ................................ .20
3.STUDY DESIGN .................................................................................................... 21
3.1. Study setting ............................................................................................... 21
3.2. Feasibility assessment ................................................................................ 22
3.3. Study design overview ................................................................................ 24
4.STUDY POPULATION/CAS E DEFINITION(S) ....................................................... 25
4.1. Study population ......................................................................................... 25
4.2. Case definitions (amended 12 November 2019) ......................................... 26
4.3. Number of subjects ..................................................................................... 26
4.4. Inclusion criteria .......................................................................................... 26
5.DATA COLLECTION AND MANAGEMENT (amended 12 November 2019) .......... 27
6.STATISTICAL METHODS ...................................................................................... 29
6.1. Primary and secondary pre- specified events of interest (amended 
12 November 2019) .................................................................................... 29
6.2. Statistical methods ...................................................................................... 29
Covariates ................................................................................... 29
Analysis of primary and secondary objectives (amended 
12 November 2019) ..................................................................... 31
Analyses interpretation ................................................................ 33
6.3. Sample size considerations ........................................................................ 33
7.STUDY CONSIDERATIONS .................................................................................. 34
8.CONDUCT OF THE STUDY .................................................................................. 34
8.1. Regulatory and ethical considerations ........................................................ 35
8.2. Informed consent and data privacy ............................................................. 35
8.3. Additional data ............................................................................................ 35
9.REFERENCES ....................................................................................................... 36
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a11 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 12LIST OF TA BLES
PAGE
Table 1 Race/ethnicity of women receiving the Tdap vaccine during 
pregnancy at seven selected medical centers at Kaiser 
Permanente Southern California, 2 016.................................................. 22
Table 2 Age of women at Tdap vaccination during pregnancy at seven 
selected medical centers at Kaiser Permanente Southern 
California, 2016 ...................................................................................... 23
Table 3 Membership among women receiving the Tdap vaccine during 
pregnancy at seven selected medical centers at Kaiser 
Permanente Southern California, 2016 .................................................. 23
Table 4 Gestational age of women at Tdap vaccination during pregnancy 
at seven selected medical centers at Kaiser Permanente 
Southern California, 2016 ....................................................................... 24
Table 5 Tdap vaccine receipt during pregnancy at Kaiser Permanente 
Southern California, 2011 -2016 .............................................................. 24
Table 6 List of primary and secondary endpoints (amended 12 November 
2019) ...................................................................................................... 29
Table 7 Analytic population and statistical methods by endpoint
(amended 12 November 2019 )............................................................... 32
Table 8 Power to rule out a two -fold increase with 15,000 pregnant 
women in each cohort ............................................................................ 33
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a12 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 13LIST OF FIGURES
PAGE
Figure 1. Illustration of data flow (amended 12 November 2019) ................................... 28
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a13 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 14LIST OF A BBREVIATIONS
ACIP Advisory  Committee on Immunization Practices
ACOG American College of Obstetrics and Gy necology
ADaM Analy sis Data Model
CA Congenital anomal y / congenital anomal ies
CDC Centers for Disease Control and Prevention
CDISC Clinical Data Interchange Standards Consortium
CI Confidence i nterval
CIOMS Council for International Organization of Medical 
Sciences
EDD Estimated date of delivery
EHR Electronic health records
FDA United States Food and Drug Administration
GPP Good Pharmacovigilance Practice
GSK GlaxoSmithKline
HIPAA Health Insurance Portability  and Accountability  Act of 
1996 (U .S.)
HIV Human immunodeficiency virus
ICD-9 International Classification of Diseases, 9thRevision
ICD-10 International Classification of Diseases, 10thRevision
IRB Institutional Review Board
ISPE International Societ y for Pharmacoepidemiology
KPSC Kaiser Permanente Southern California
MRN Medical r ecord number
OB-GYN Obstetrics and Gy necology
PHI Protected 
health i nformation
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a14 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 15PPROM Preterm pre -labor rupture of membranes
REDCap Research Electronic Data Capture
RIPC Regional Immunization Practices Committee
SAS Statistical Analy sis Software
SDTM Study  Data Tabulation Module
SGA Small for gestational age
Tdap Tetanus, diphtheria, acellular pertussis 
U.S. United States
VAERS Vaccine Adverse Event Reporting S ystem
VSD Vaccine Safet y Datalink
WHO World Health Organization
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a15 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 16GLOSSA RY OF TERMS
Adverse Events: Pre-specified, pregnancy -related diagnoses or pregnancy  
outcomes or infant diagnosis to be compared between the 
exposed and unexposed cohorts. 
Cohort study: Epidemiology  study  where subjects in a study  population 
are classified according to their exposure status and 
followed over time to ascerta in the outcome(s). 
Database study: A study  involving the use of pre -existing data maintained 
in an electronic format.
End of study : For database studies, end of study is the date the database 
analysis is complete. For this study , that is the date the 
analysis of congenital anomaly  (among KPSC -born 
infants through 6 months of age) is complete . 
Exposed cohort (from 
the 27thweek of 
gestation )
:Subjects classified as exposed to Tdap (Boostrix) on the 
1stday of the 27thweek of 
gestation or later. 
eTrack: GSK‚Äôs tracking tool for clinical/epidemiology  studies.
Health Connect: Electronic health record sy stem which is the legal record 
of all received medical care within the KPSC health care 
system.
Index date of the 
matched pair of exposed 
and unexposed pregnant 
women :The unexposed cohort of pregnant women will be 
matched 1:1 to the exposed group of pregnant women for 
comparisons of maternal and infant adverse events 
between the two cohorts. The matched pair will have an 
index date, which is determined by  the number of days 
from pregnancy  start to Boostrix vaccination of the 
exposed woman. Every  unexposed woman will be 
assigned an index date that is determined b y the number 
of day s from pregnancy  start to the Boostrix vaccination 
date of her matched exposed woman. The sa me number 
of day s calculated in the exposed woman will be added to 
the pregnancy  start of the unexposed woman to identify  
her index date. Both groups will be followed from the 
index date to the events of interest and pregnancy  
outcomes.
Pregnancy start: Corresponds to a gestational age of 0 weeks based on the 
most reliable estimated date of delivery . 
Completion date: The date of final collection of data for all outcomes.
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a16 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 17Retrospective study: A study  that looks backward in time (e.g. at events that 
occurred in the past; outcomes and exposure can no 
longer be influenced), usually  using medical records, 
databases or interviews in order to address one or more 
study  endpoints. 
Subject: Term used throughout the protocol to denote a person 
about whom some medical information has been recorded 
in a database.
Unexposed cohort: Subjects classified as not exposed to any  Tdap vaccine 
during the pregnancy  under study
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a17 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 181. INTRODUCTION
1.1. Background
Whooping cough, also referred to as pertussis, is a highl y contagious respiratory disease 
primarily  caused b y the bacterium Bordetella pertussis. The disease is most severe in 
unvaccinated or incompletely  vaccinated infants, who may  develop apnea, seizures
secondary  to hy poxia, pulmonary  hypertension, pneumonia ,otitis media , and death (3).
Cyclical increases in pertussis incidence continue to be described every  3 to 5 y ears in 
most developed countries despite high vaccination coverage. This is explained largel y by 
waning immunity  both after vaccination and after natural infection (4-6). 
Two tetanus
-diphtheria- acellular pertussis (Tdap) vaccines (Adacel and Boostrix) were 
licensed for use in the United States (U.S.) in 2005 ( 7). These vaccines were 
recommended for routine use in non -pregnant ad olescents and adults when introduced. In 
2010, the California Department of Health began recommending Tdap vaccine to women 
at an y stage of pregnancy in response to a pertussis outbreak and several infant deaths
(8).One year later, the Advisory  Committee on Immunization Practices (ACIP) advised 
Tdap to be administered during pregnancy , at 20 weeks gestation or later, to women who 
had not been previously  vaccinated (9).In October 2012, ACI P expanded its 
recommendation of administering Tdap during pregnancy (10); in order to increase the 
protection of newborns, all pregnant women should be offered Tdap, regardless of 
whether they
 have received Tdap previously . While the ACI P recommends that optimal 
timing for Tdap administration is between 27 a nd 36 weeks gestation to optimize transfer 
of anti -pertussis antibodies, Tdap may  be given at any  time during pregnancy . Both 
Adacel and Boostrix can be used interchangeably .
Prelicensure clinical study data showed that the incidence of unsolicited adverse events 
reported in the 31 day s after vaccination was comparable between recipients of Boostrix 
and Adacel (17.8% and 22.2% for Boostrix and Adacel, respectivel y). Serious adverse 
events during 0 -6 months following vaccine were reported by  1.4% and 1.7% of subjects, 
respectivel y. During the 6
-month extended safet y evaluation period, no serious adverse 
events of a neuroinflammatory  nature or with information suggesting an autoimmune 
etiology  were reported in subjects who received Boostrix (11).
Safety  events 
following Tdap immunization during pregnancy  have been increasingl y 
examined in recent years. A placebo- controlled clinical trial of Adacel administered to 
pregnant women ( 2008- 2012 )found no Tdap- associated serious adverse events (12).
During a time when Tdap was not routinely  recommended for pregnant wo men, 
spontaneous abortions were the most frequent pregnancy -specific adverse events (16.7%) 
identified through the Vaccine Adverse Event Reporting S ystem (VAERS), a national 
database used for monitoring the safet y of vaccines in the population ( 13). However, the 
number of pregnant women who received the vaccine was small (n=132) and likely  a 
selective group since the vaccine was not in routine use. Asmall study  observing a 
limited number of maternal and infant outcomes (chorioamnionitis, postpartum 
endometritis, premature rupture of membranes
, 5-minute Apgar score, birth defects ) also 
found no Tdap -associated adverse events (14)
.However, the authors found that Tdap was 
associated with women having decreased odds of cesarean delivery . In a study  of 2010 -
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a18 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 192012 live births in twoCalifornia health care systems partic ipating in the Vaccine Safet y 
Datalink (VSD) project, no associations between Tdap and maternal hy pertensive 
disorders were found, although a small but statistically  significant increased risk of 
chorioamnionitis was observed (6.1% in vaccinated, 5.5% in unvaccinated) (15),a 
finding 
consistent with alarger subsequent study  at seven U.S. health care sy stem VSD 
sites ( 16). An increased risk of chorioamnionitis was also found in a different U.S.- based 
study  of over one- million pregnant women (2010 -2014), which also found anincreased 
risk of postpartum h
emorrhage, one case of post -immunization anaphy laxis ,and 12 cases 
of post -delivery  encephalopathy  (17) . However, this study  did not find a significant 
association with preeclampsia/eclampsia or premature rupture of membranes. An 
evaluation of acute events post vaccination found no associations betwee n Tdap 
immunization and a composite outcome of acute events , incident neurologic events or
thrombotic events, or proteinuria in alarge VSD cohort ( 18).Additionally ,a study  of 
infant outcomes found that Tdap wasnot significantly  associated with increased risk for 
structural birth defects or microcephal y for vaccinations given during any  week of 
pregnancy  
(19). Except for the afore mentioned VSD studies in which Adacel comprised 
the majority  of Tdap vaccines administered (15),the Tdap product in the other studies 
was not explicitly  mentioned. 
Considering that Boostrix is recommended to be used interchangeabl y with Adacel, and
there are limited observational safet y data on Boostrix during pregnancy, a post -
marketing stud y describing the safet y of Boostrix vaccine in pregnant women is 
particularl y necessary  and can provide timel y safety  information to the public and 
healthcare providers.
1.2. Rationale for the study
The rationale for the current study  is to assess the safet y of Boostrix administered on or 
after the 1stday of the 27thweek of pregnancy  by conducting a post -marketing study  that 
will provide safet y information to the public and healthcare providers. This will be one of 
the largest cohorts of pregnant women vaccinated with Boostrix in the U
.S. Through 
partnership 
between Kaiser Permanente Southern California (KPSC) and the sponsor, 
GlaxoSmithKline (GSK), w e will provide information about the safet y of maternal 
vaccination with Boostrix and maternal and infant adverse events in a community  setting. 
The observational stud y design takes advantage of KPSC‚Äôs electronic health record 
(EHR) system , Health Connect . We will capture adverse events following Boostrix 
vaccination in pregnant women and adverse events in an unexposed historical 
comparison cohort of pregnant women . Retrospective ascertainment of pregnant women 
through Health Connect is an efficient strategy in comparison to a recruitment study , 
which would be practically  and financiall y infeasible because pregnant women are not 
likely  to enroll in safety  stud ies.
Primary  endpoints were differentiated from secondary  endpoints to allow evaluating the 
safet y of maternal vaccination with sufficient power on the primary  endpoints and to 
allow 
for hypothesis generation/signal detect ion on secondary  endpoints.
Primary  endpoints were selected based on their medical relevance, considering also the 
background incidence or prevalence of these endpoints .
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a19 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 202. OBJECTIVE
2.1. Primary  objective
To rule out a two-fold increase (non- inferiorit y testing) in the incidence of each of the 
following maternal and infant adverse events
:
ÔÇ∑Preeclampsia and/or eclampsia
ÔÇ∑Intra -uterine infections such as chorioamnionitis andendometritis
ÔÇ∑Small for gestational age (SGA)
ÔÇ∑Preterm delivery
among women who were vaccinated with Boostrix on or after the 1stday of the 27thweek 
of gestation as compared to the incidence in a historical cohort of pregnant women 
(approximately  January  1, 2012 to December 31, 2013) who were unvaccinated with any  
Tdap vaccine throughout their pregnancy .
2.2. Secondary  objectives (amended 12November 2019
)
1.To explore differences (superiority testing) in the incidence rate of other maternal 
and infant adverse events, namely :
ÔÇ∑Transfusion during delivery hospitalization (as a proxy for severe post -partum 
hemorrhage)
ÔÇ∑Poor fetal growth
ÔÇ∑Stillbirth/fetal death with or without congenital anomalies
ÔÇ∑Neonatal death (within 28 day s of birth)
ÔÇ∑Maternal death (while pregnant or within 42 day s of end of pregnancy ) 
ÔÇ∑Placental abruption
ÔÇ∑Preterm pre -labor rupture of membranes (PPROM)
ÔÇ∑Congenital anomalies (CA) at birth and through 6 months of age
between women who were vaccinated with Boostrix on or after the 1stday of the 27th
week of gestation and a historical cohort of pregnant women ( approximately  January  
1, 2012 to December 31, 2013) who were unvaccinated with any  Tdap vaccine 
throughout their pregnancy .
2.To describe the 
incidence of maternal and infant adverse events described above, as 
well as the incidence of spon taneous and therapeutic abortion with or without 
congenital anomalies, in pregnant women who were vaccinated with Boostrix before 
the 27thweek of gestation.
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a20 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 213. STUDY DESIGN
3.1. Stud y setting
KPSC is an integrated healthcare s ystem that provides comprehensive prepaid health 
services for its 4.4 million members. There are 1 5medical centers that include a total of 
225 medical office buildings throughout Southern California. Members are raciall y 
diverse and include the entire socio -demographic spectrum, and over 99% are 
community -dwelling. The demographic makeup of the KPSC membership closely  
mirrors the Southern California population and the California c ensus population 
(20).
Compared to the racial/ethnic distribution of the 
U.S. population, the KPSC membership 
has twice as man y individuals of Asian descent and three times as man y Hispanics. Data 
regarding demographics, services ,diagnoses , and procedures are tracked in the KP SC 
EHR ( Health Connect ) from the outpatient, emergency  department, and hospital settings. 
Health Connect is the legal record of all medical care received within the KPSC sy stem. 
Records of vaccinations and medical events can only  be entered b y medical staf f. 
Pharmacy  records and vaccination sare linked through patients‚Äô unique medical record 
numbers (MRNs). Vaccinations received outside of the health plan are recorded with 
appropriate documentation.
KPSC is a pre -paid health care s ystem. Vaccines are typicall y provided to KPSC 
members at no charge, which is an incentive for members to receive immunizations 
within the sy stem. Also, there is a very  strong motivation for members to use services 
internally . For outside providers to be reimbursed by  the hea lth plan for covered 
emergent or contract care, claims must be submitted with documentation of the episode 
of care. Thus, the capture of care delivered to members by  electronic administrative data 
is reasonabl y assumed to be very comprehensive. The KPSC Re gional Immunization 
Practice Committee (RI PC) makes recommendations to ensure appropriate use of 
vaccination and implementation of new ACIP immunization recommendations within 
KPSC.
Standard of care regarding use of Tdap in pregnant women
On October 24, 2012, ACI P voted to recommend Tdap for pregnant women with every  
pregnancy irrespective of previous Tdap history . In December 2012, the KPSC RI PC 
followed ACI P guidance and recommended that providers of prenatal care implement a 
Tdap immunization program fo r all pregnant women. The g uidance indicated that all 
health- care personnel should administer a dose of Tdap during each pregnancy  
irrespective of the patient‚Äôs prior history  of receiving Tdap. In order to maximize the 
maternal antibod y response and passive antibody  transfer to the infant, optimal timing for 
Tdap administration was specified between 27 and 36 weeks gestation.
Prior to the conduct of this observational study  of Boostrix in pregnancy , Adacel had 
been the onl y Tdap vaccine on the KPSC formular y. 
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a21 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 22Process for identify ing pregnancy  information
If a woman receives prenatal care at KPSC ,her pregnancy is recorded in a pregnancy  
episode flowsheet. Theflowsheet is contained in the woman‚Äôs medical record and is 
created at the beginning of the pregnan cy. It is appended with all pregnancy  encounters 
including prenatal visits, the hospital admission for birth, a s well as an y post-partum 
visits. Pregnancy and birth information at KPSC including maternal age, pre- pregnancy  
height and weight, perinatal risk factors, prenatal visit information, complications of 
pregnancy  and delivery , and procedures used during labor and delivery  are available from 
the EHR and can be viewed in Health Connect. 
Process for linking mothers and infants
As standard of care at KPSC, all infants born in KPSC hospitals are automatically  
assigned a MRN regardless of whether the mother is a current plan member.  If the 
mother is a current member, the bab y‚Äôs MRN is automatically  linked to her medical 
record in her pregnancy  episode flowsheet. 
3.2. Feasibility  assessment
The following tables display  data to describe Tdap v accination among pregnant women at 
seven selected KPSC medical centers that will administer the Boostrix vaccine. 
Approximately  15,000 women vaccinated with Boostrix will be included in this study ,
over approximately  a one -year period .
Pregnant women receiving the Tdap vaccine
The following table provides demographic information on pregnant women receiving the 
Tdap vaccine at seven selected medical centers at KPSC (Table 1) . There were 19,804 
pregnant women receiving the vaccine within these medical centers in 2016. 
Over half of 
themwere of Hispanic race/ethnicity  (57%). The age distribution shows that pregnan t 
women aged 27 -35 years old made up more than half (55%) of the Tdap -exposed 
pregnant women (Table 2). 
Table 1 Race/ethnicity of women receiving the Tdap vaccine during 
pregnancy  at seven selected medical centers at Kaiser Permanente 
Southern California, 2016
Mother‚Äôs race/ethnicity Frequency Percent
Asian 2,494 12.6%
Black 1,643 8.3%
Hispanic 11,354 57.3%
Multiple 512 2.6%
Native American/ Alaskan 11 0.1%
Others 24 0.1%
Pacific Islander 23 0.1%
Unknown 33 0.2%
White (Non -Hispanic white) 3,710 18.7%
TOTAL 19,804 100%
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a22 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 23Table 2 Age of women at Tdap vaccination during pregnancy  at seven 
selected medical centers at Kaiser Permanente Southern California, 
2016
Mother‚Äôs age at vaccination (years) Frequency Percent
15-26 5,785 29.2%
27-35 10,858 54.8%
36-45 3,132 15.8%
>45 29 0.2%
TOTAL 19,804 100%
Membership among Tdap vaccinated pregnant women
At seven selected medical centers within KPSC, 18,875 (95.3%) pregnant women had 
continuous 
members hip(allowing up to a 31 -day gap) at least from the start of the 2 7th
week of pregnancy  (Table 3). There were 16,147 (82%) women who were members since 
the beginning of pregnancy .
Table 3 Membership among women receiving the Tdap vaccine during 
pregnancy  at seven selected medical centers at Kaiser Permanente 
Southern California, 2016
Membership during pregnancy * Frequency Percent
Gestation: 0 to 2 6weeks only 260 1.3%
Gestation: 2 7weeks to delivery only 2,728 13.8%
Gestation: 0 weeks to delivery 16,147 81.5%
Partial membership** 669 3.4%
TOTAL 19,804 100%
* Represents women with membership (allowing up to a 31 -day gap) during the entire indicated period.
** 447 had membership during the post- vaccine pregnancy period
Gestational age at Tdap vaccination
There were 19,554 (98.7%) pregnant women who received Tdap vaccination at or after 
27 weeks of pregnancy  (Table 4). There were 18,611 (94.0%) women who were 
vaccinated between 27 and 36 weeks gestation.
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a23 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 24Table 4 Gestational age of women at Tdap vaccination during pregnancy  at 
seve n selected medical centers at Kaiser Permanente Southern 
California, 2016
Gestation al age at vaccination Frequency Percent
<27 weeks 250 1.3%
27 weeks to 32 weeks 15,111 76.3%
33weeks to 36 weeks 3,500 17.7%
>36 weeks 943 4.8%
TOTAL 19,804 100%
Note: Only those women meeting eligibility criteria, including membership, will be included in the analysis.
Rationale for h istorical comparison cohort 
The estimated period of1/1/2012 -12/31/2013 was chosen for the unvaccinated 
comparison group because Tdap uptake ranged between 27% and 38% during this time 
(Table 
5). The aim is to restrict the unvaccinated population to approximately 2012 -2013
tominimize the concerns of confounding b y indication. Given that Tdap uptake exceeded 
65% starting in 2014 , aconcurrent unvaccinated cohort will y ield a small and selective 
sample , and is not represen tative of an unvaccinated group.
Table 5 Tdap vac cine receipt during pregnancy  at Kaiser Permanente 
Southern California, 2011 -2016
Tdap during pregnancyNo Tdap during pregnancy
Year Frequency Percent Frequency Percent
2011 18325 40.0% 27471 60.0%
2012 13128 27.6% 34486 72.4%
2013 18309 38.3% 29519 61.7%
2014 32660 65.3% 17366 34.7%
2015 35754 68.4% 16513 31.6%
2016 38475 69.3% 17058 30.7%
3.3. Stud y design overview
The study  design is an observational retrospective matched cohort stud y. This proposed 
research will be conducted among pregnant women who are members of KPSC . 
The exposed cohort will consist of pregnant women irrespective of their risk profile (low 
or high-risk) who receive dthe Tdap vacc ine (Boostrix) on or after the 1st day of the 27th
week of pregnancy  during the vaccination period at ob -gyn clinics of seven selected 
medical centers. 
Approximately  15,000 women vaccinated with Boostrix will be included in this study  
over approximately  a one-year period. The unexposed cohort will consist of pregnant 
women during the approximate estimated period from 1/1/2012 to 12/31/2013 who never 
received Tdap vaccine during pregnancy . 
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a24 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 25Of note, women vaccinated with Boostrix before the 27thweek of gestation , with 
membership at the date of vaccination, and who were not vaccinated with any  other Tdap 
vaccine at an y other time during the pregnancy in scope of this study will be part of a 
descriptive analy sis (secondary  objective).
Subject -level data will be collected for pregnant women and their infants through the 
EHR .For each individual pregnant woman, analytical follow up will begin on the date 
they receive the Boostrix vaccine ,or the index date for the unvaccinated cohort, and will
end on the date of disenrollment or the end of pregnancy , whichever c ame first. For the 
maternal death endpoint, pregnant women will be followed for 42 day s after theend of 
pregnancy .Infants born in KPSC hospitals will be followed for 6 months.
4. STUDY POPULA TION/CA SE DEFINITION(S)
4.1. Stud y population
The exposed and unexposed cohort swill consist of pregnant women with evidence of
prenatal care and continuous members hip(allowing up to a 31 -day gap) at KPSC 
between the 1stday of the 27thweek of gestation and the index (vaccination) date .
Women will be considered exposed if they  receive d Boostrix on or after the 1stday of the 
27thweek of gestation at selected ob -gyn clinics at seven medical centers throughout 
KPSC (vaccination period planned to begin in January  2018). U nexposed p regnant 
women comprise women pregnant sometime during the approximate estimated period 
between 1/1/2012 and 12/31/2013 who did not receive an y Tdap vaccine during 
pregnancy .If needed, we will consider adding additional yearsto increase the eligible 
number of unexposed pregnant women. Gestational age will be estimated from the most 
reliable estimated date of delivery  (EDD) which is based on the last menstrual period, the 
first accurate ultrasound examination, or both. Obstetric providers are recommended to
reference guidelines from the American College of Obstetrics and Gy necology (ACOG) 
to calculate EDD (21). Pregnancy  start date will correspond to a gestational age of 0 
weeks. 
Matching process for pregnant women who were vaccinated with Boostrix after the 27th
week of gestation
The unexposed cohort w ill be matched 1:1 to the exposed group for comparisons of 
maternal and infant adverse events between the two cohorts . Every  unexposed woman 
will be assigned an index date that is determined by the number of da ys from pregnancy  
start to the Boostrix vaccination date of her matched exposed woman. The same number 
of day s calculated in the exposed woman will be added to the pregnancy  start of the 
unexposed woman to identify  herindex date. 
Existing health conditions, age, lifest yle factors, and conditi ons of pregnancy can place a 
pregnancy  at risk (22).Therefore, matching variables include maternal age at pregnancy  
start (¬± 1 y ear), race/ethnicity  (White, Blac k, Hispanic, Asian, and Other) and multiple 
gestation
.Other pregnancy  high -risk conditions will be considered as potential covariates 
in the anal ysis (see Section 6.2.1 Covariates). 
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a25 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 26For example, suppose there is a 28 -year-old (at pregnancy  start ) Hispanic pregnant 
woman expecting twins with a pregnancy  start date of 2/18/2018 receiving Boostrix on 
8/30/201 8on the 194th day  of her pregnancy  (from pregnancy  start date to vaccination). 
We will match her with a Hispanic woman pregnant sometime between 1/1/2012 and 
12/31/2013, who was 27 -29 years of age at pregnancy start and hada multiple gestation 
pregnancy , with an index date assigned to be the 194thday of pregnancy , and who never 
received Tdap vaccine during pregnancy .If a match is not feasible within the proposed 
two-yearperiod , the pool of unexposed women canbe expanded to include unexposed 
pregnant women from additional y ears. Both groups will be followed for events of 
interest from the index date. In this example, both women will be followed from the 
194th day  of their pregnancy .
4.2. Case definitions (amended 12November 201 9
)
Endpoints of interest will be extracted from the EHR using the pregnancy  episode 
flowsheet, diagnosis codes (ICD -9 and ICD -10 codes), procedure codes, ordeath records . 
While these events are recorded as part of routine care, in general, ACOG recommended 
guidelines are used b y KPSC providers to diagnose and manage these conditions 
(23-31).
With th e exception of SGA , preterm delivery ,and transfusion, chart review will be 
performed for the pre -specified maternal and infant adverse events to confirm the events
and that the events are incident after the index date.
4.3. Number of subjects
Approximately  15,000 pregnant women vaccinated with Boostrix over a period of 
approximately  one year. Unexposed pregnant women, matched 1:1 to the exposed group, 
will be identified from a historical cohort. Therefore, we aim to have a total sample size 
of approximately  30,000 pregnant women. 
4.4. Inclusion criteria
ÔÇ∑Pregnant women with prenatal care and continuous membership (allowing up to a 
31-day gap) at KPSC between the 1st day  of the 27th week of gestation and the 
index (vaccination) date.
ÔÇ∑Exposed cohort (from the27th week of gestation): Pregnant women vaccinated with 
Boostrix on or after the 1st day  of the 27th week of gestation ; who were not 
vaccinated with an y other Tdap vaccine at an y other time during the pregnancy in 
scope of this study . 
ÔÇ∑Unexposed c ohort: Women matched to the exposed cohort and pregnant sometime
during the approximate estimated period between 1/1/2012 -12/31/2013 and did not 
receive an y Tdap vaccine during the pregnancy  in scope of this study .
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a26 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 27For the anal ysis of congenital anomalies among live births, at birth and through six 
months of age, the following additional inclusion criteria for infants will be applied :
ÔÇ∑Live born
ÔÇ∑Born in KPSC hospitals 
Note: 
Pregnant women vaccinated with Boostrix during pregnancy  before the 27thweek 
of gestation , with membership at the date of vaccination, and who were not vaccinated 
with any  other Tdap vaccine at any  other time during the pregnancy  in scope of this study  
will be part of a descriptive anal ysis (secondary  objective). 
5. DATA COLLECTION A ND MANAGEMENT (amended 12
November 201 9)
Vaccination and medical event data will be extracted directl y from the EHR (Health 
Connect) , which is the legal record of all medical care received within the KPSC sy stem.
Figure 1provides an overview of the data flow for this study .All details of a patient 
encounter, including diagnoses, procedures, and physician‚Äôs notes, are entered into the 
EHR at the point of ca re.All vaccinations are entered into the EHR when they  are given, 
with vaccine, dose, manufacturer, and lot number entered at the time of vaccination. 
Vaccinations received outside of the health plan are recorded with appropriate 
documentation. Records of vaccinations and medical events can onl y be entered b y 
medical staff. Endpoints of interest will be extracted from the EHR using the pregnancy  
episode flowsheet, diagnosis codes (ICD -9 and ICD -10 codes ), procedure codes, or death 
records . 
We will rely  on automated data from the EHR to ascertain SGA , preterm delivery , and 
transfusion . For other endpoints, c hart abstraction will be performed for the pre - specified 
maternal and infant adverse events to confirm the event and that they  are incident after 
the index date when applicable (i.e., events diagnosed during pregnancy  that may  have 
onset prior to index date). Events will be reviewed in the chart in which the incident 
diagnosis code is identified (i.e., mother‚Äôs chart or infant‚Äôs chart) .Unknown pregnancy  
outcomes and KPSC live born singleton infants with unknown birthweight will also be 
chart reviewed. Chart abstractors will not be masked to the exposure status as they  will 
have access to the entire medical record within Health Connect, includin g vaccination 
status. Data will be abstracted directly  from Health Connect. For the chart abstracted 
data, the study  team will develop a chart abstraction form in the Research Electronic Data 
Capture s ystem ( REDCap ) and a chart abstraction manual ( 32). The chart abstraction 
manual will be developed for the purposes of ensuring standardization and uniformity  of 
data collection among the chart abstractors. The ch art abstraction manual may include
guidance on how to navigate through the EHR to search for pertinent information 
(including screenshots of the EHR for reference), directives for how to address questions
in the abstraction form, and explanation s
of clinical terms and other variable definitions. 
A sample of abstraction forms will be quality  checked by  a second person. Logic and data 
range checks will be performed on the abstracted data collected electronically  in 
REDCap.
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a27 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 28Electronic data and chart reviewed d ata will be combined into a Statistical Analy sis 
Software ( SAS)
dataset for anal ysis. Double programming will be performed to check the 
total number of eligible subjects included in the analy sis. All other programming will be 
reviewed b y a second person. T he results of the original and validation programming will 
be compared, an y discrepancies will be investigated, and action will be taken to resolve 
discrepancies. 
The study  datasets will be formatted according to Clinical Data Interchange Standards 
Consor tium (CDI SC). We will develop specifications to include information about the 
number of domains, mapping rules, and will output the dataset according to the SAS 
study  dataset, required analy sis report and CDISC implementation guide; map the 
original SAS da ta to the domains according to the specification to create Study  Data 
Tabulation Module ( SDTM )and Anal ysis Data Model ( ADaM ) datasets; validate the 
SDTM and ADaM datasets using an open source CDI SC validation program (e.g., 
Pinnacle 21 ); and produce submission documentation including DEFINE.XML  and Study  
Data Reviewers Guide for SDTM and AD aM.
Figure 1. Illustration of data flo w(amended 12November 2019)
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a28 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 F inal
12-NOV -2019 296. STATISTICA L METHODS
This study  will involve both descript ive and multivariable anal yses, and all anal yses will 
be conducted using the SAS statistical software package (version 9.3 or later ). 
6.1. Primary  and secondary pre-specified events of interest
(amended 12November 201 9
)
The pre-specified events of interest arematernal and infant outcomes identified from 
KPSC‚Äôs EHR sy stem using thepregnancy  episode flowsheet, diagnosis codes , procedure 
codes, or death records for the exposed and unexposed groups . While these events are 
recorded as part of routine care, i n general, ACOG recommended guidelines are used b y 
KPSC providers to diagnose and manage these conditions (23-31). In addition, we will 
use a commonly  accepted definition to identify  congenital anomalies, such as that used 
by the National Birth Defects Prevention Network (33).Additional birth outcomes will 
be captured for descriptive purposes, but not considered adverse event s: birth length, 
head circumference , and Apgar scores . To avoid capture of preexisting conditions, 
diagnostic codes representing each condition should not appear prior to the index date 
within the pregnancy under study .All pre-specified events of interest will be collected 
through the completion date .Anal yses will be done on chart confirmed incident events
when applicable .
Table 6 List of primary  and secondary  endpoints (amended 12November 
201
9)
Primary endpoints Preeclampsia and/or eclampsia
Intra-uterine infections such as chorioamnionitis andendometritis
Small for gestational age (SGA)
Preterm delivery
Secondary 
endpointsTransfusion during delivery hospitalization 
Poor fetal growth
Stillbirth/fetal death with or without congenital anomalies
Neonatal death (within 28 days of birth)
Maternal death (while pregnant or within 42 days of end of pregnancy )
Placental abruption
Preterm pre -labor rupture of membranes (PPROM )
Congenital anomalies at birth and through 6 months of age
Spontaneous abortion with or without congenital anomalies (only for women exposed to 
Boostrix before the 27thweek of gestation )
Therapeutic abortion with or without congenital anomalies (only for women exposed to 
Boostrix before the 27thweek of gestation )
6.2. Statistical methods
Covariates
Baseline characteristics of pregnant women and information on other relevant covariates 
will be extracted through automated data. Data will be in the form of International 
Classification of Diseases, 9thor 10thRevision ( ICD -9 or ICD- 10)codes orstructured 
data fields .While data on these characteris ticswill be collected, onl y the potential
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a29 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 30confounders associated with the exposure or outcome will be considered in adjusted 
analyses and will be a subset of the 
covariates of interest. Identification of the potential
confounders will be determined through bivariate anal yses and b y prior knowledge based 
on the literature (22) .
Medical conditions indicative of a high -risk pregnancy  to be considered as covariates 
include:
ÔÇ∑thyroiditis,
ÔÇ∑diabetes, 
ÔÇ∑other autoimmune diseases (mixed connective tissue disease such as s ystemic lupus 
erythematosus), 
ÔÇ∑renal and cardiac chronic diseases, 
ÔÇ∑obesity (pre-pregnancy  BMI>40) , 
ÔÇ∑pre-existing hy pertension, 
ÔÇ∑Rhesus sensitization, 
ÔÇ∑HIV infection, 
ÔÇ∑syphilis infection,
ÔÇ∑cervical incompetence .
Some additional covariates of interest to be collected and explored (if data are available)
include: 
ÔÇ∑smoking status
ÔÇ∑alcohol use
ÔÇ∑length of membership prior to 27 weeks gestation (but after pregnancy  start) 
ÔÇ∑health care utilization (receipt of medical care) prior to the index date (but after 
pregnancy  start)
ÔÇ∑number of previous pregnancies 
ÔÇ∑history  of pregnancy  loss
ÔÇ∑receipt of other vaccines during pregnancy , e.g., 
influenza vaccine
ÔÇ∑receipt of vaccines containing diphtheria, tetanus toxoid or pertussis containing 
antigens within one y ear before pregnancy  
ÔÇ∑season of pregnancy  start
ÔÇ∑Medicaid insurance (public health insurance: Indication of low income status)
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a30 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 F inal
12-NOV -2019 31
Analysis of primary  and secondary objective s(amended 12
November 201 9)
Demographics andpregnancy  information will be compare d between the exposed and 
unexposed cohorts. Bivariate anal yses will be conducted for all covariates of interest. 
Continuous variables will be summarized by  means, medians, ranges, and standard 
devia tions and compared using t -tests; categorical variables will be summarized by  
frequency  distributions and compared using chi- square tests for the exposed and 
unexposed groups. Potential confounders will be determined based on bivariate anal yses 
and scientific relevance.
For events identified at delivery  such as SGA , preterm delivery , and transfusion during
delivery hospitalization ,we will calculate crude incidence and 95% confidence intervals 
(CI) for each adverse event for the exposed and unexposed groups. The incidence of each 
maternal adverse event during pregnancy  will be calculated separately and will consist of 
the total number of women with the condition in the numerator and the number of women 
for whom the condition can be assessed in the denominator .The adjusted relative risk 
with CI  will be estimated by  a Poisson regression model with adjustment for potential 
confounders. If the outcome is common (i.e., incidence> 2%), a Poisson regression model 
with robust variance estimation will be used to estimate the relative risk ( 34). For primary  
endpoints ,a two-sided 98.75% CI will be used for the relative risk with multiple 
comparison adjustment ,while for secondary  endpoints a two-sided 95% CI will be used. 
For events identified an y time after the index date such as intra -uterine infection, we will 
calculate crude incidence and 95% CI for each adverse event for the exposed and 
unexposed groups. The incidence of each maternal adverse event during pregnancy will 
be calculated separatel y and will consi st of the total number of women with the condition 
in the numerator and the total person time in the denominator. The person- year for a 
pregnant woman will be the time from the index date to the date of each adverse event ,
end of the pregnancy ,or disenrol lment , whichever comes first .The adjusted relative risk 
with CI  will be estimated by  a Poisson regression model accounting for the follow -up 
time with adjustment for potential confounders. If the outcome is common (i.e., 
incidence>2%), a Poisson regression model with robust variance estimation will be used 
to estimate the relative risk. For primary endpoints ,a two-sided 98.75% CI will be used
for the relative risk with multiple comparison adjustment ,while for secondary  endpoints 
a two-sided 95% CI  will be used.
Congenital anomalies will be identified at birth and through 6months of age among 
infants born in KPSC hospitals .Most congenital anomalies are diagnosed by 6 months of 
age (35). The prevalence of congenital anomalies (overall ,by type, at birth ,and through 6 
months of age ) will be calculated as the number of infants with a congenital anomaly in 
the numerator and the total number of infants born in KPSC hospitals in the denominator. 
The proportion of live births without congenital anomalies will be calculated as 1 minus 
the proportion of live births with congenital anomalies among all KPSC live born infants .
The adjusted re lative risk with 95% CI will be estimated by  a Poisson regression model 
with adjustment for potential confounders. If the outcome is common (i.e., incidence
>2%), a Poisson regression model with robust variance estimation will be used to 
estimate the relative risk.
The following table outlines the planned method of anal ysis by endpoint.
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a31 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 32Table 7 Analytic population and statistical methods by  endpoint (amended 12November 201 9)
Primary endpoints Analytic population Statistical Methods
Preeclampsia and eclampsia All pregnant women eligible for inclusion/exclusion criteria Adjusted Poisson regression model accounting for follow up time, 
with robust variance estimate
Intra-uterine infections such as chorioamnionitis
and endometriti sAll pregnant women eligible for inclusion/exclusion criteria Adjusted Poisson regression model accounting for follow up time, 
with robust variance estimate
Small for gestational age (SGA) KPSC live born infant, singleton only** Adjusted Poisson regression model, with robust variance 
estimate
Preterm delivery Pregnant women with live birth, with index (vaccination) date 
prior to 37 weeks gestationAdjusted Poisson regression model, with robust variance 
estimate 
Secondary endpoints Analytic population Statistical Methods
Transfusion during delivery hospitalization Pregnant women with delivery hospitalization Adjusted Poisson regression model
Poor fetal growth All pregnant women eligible for inclusion/exclusion criteria Adjusted Poisson regression model accounting for follow up time, 
with robust variance estimate
Stillbirth/fetal death* Pregnant women with pregnancy outcome Adjusted Poisson regression model 
Neonatal death (within 28 days of birth) KPSC live born infants Adjusted Poisson regression model 
Maternal death (while pregnant or within 42 
days of end of pregnancy)All pregnant women eligible for inclusion/exclusio n criteria Adjusted Poisson regression model accounting for follow up time
Placental abruption All pregnant women eligible for inclusion/exclusion criteria Adjusted Poisson regression model accounting for follow up time
Preterm pre -labor rupture of membranes 
(PPROM)All pregnant women, with index (vaccination) date prior to 37 
weeks gestationAdjusted Poisson regression model accounting for follow up time
Congenital anomalies (CA) at birth and through 
6 months of ageKPSC live born infants Adjusted Poisson regression model, with robust variance 
estimate if outcome is common
Spontaneous abortion Pregnant women exposed to Boostrix before the 27th week 
of gestation Descriptive analysis (proportion)
Therapeutic abortion Pregnant women exposed to Boos trix before the 27th week 
of gestation Descriptive analysis (proportion)
* Stillbirth/fetal death will be described with or without congenital anomalies separately , but will be analyzed as one outcome .
** There are no well accepted SGA metrics for infants born to pregnant women with multiple gestation .
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a32 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 F inal
12-NOV -2019 33
Analyses interpretation
Analy sis of primary  endpoints will be used to evaluate the safet y of maternal vaccination 
and concluded to be non-inferior if the upper limit of the 98.75% CI for the adjusted 
relative risk is below 2.
While the analy sis of primary  endpoints will be used to evaluate the safet y of maternal 
vaccination with sufficient statistical power , the analy sis of secondary  endpoints will be 
used for h ypothesis generation/signal detection.
6.3. Sample size considerations
The power computation for the primary  objective was performed using PASS non -
inferiority  of two independent proportions using Miettinen and Nurminen method. 
Although th e power is not based on the Poisson regression model, it is expected to reflect 
the power on the planned anal ysis since inference on proportion and incidence rate 
provide similar results when incidence rates are low.
The following table ( Table 8) shows the power to rule out a two- fold increase considering 
an assum edpossible design bias leading to a 1.25 relative risk increase . 
To be able to make i ndependent conclusions for each of the four primary  endpoints while 
controlling the t ype I error below 2.5% ,a Bonferroni adjustment will be used , i.e., each 
primary  endpoint will be evaluated using a one-sided 0.625% (2.5% type Ierror / 4
primary  endpoints ) nominal type I error. More specificall y,the upper limit of the two-
sided 98.75% CI  will be used to make conclu sions .
Considering that the four primary  endpoints are expected to have an incidence rate above 
1%, the power to conclude that maternal immunization is non- inferior for anyprimary  
endpoint is at least 95% and the power to conclude that maternal immunization is non -
inferior for all 4 primary  endpoints is at least 80% (100% - 4*beta).
Table 8 Power to rule out a two -fold increase wi th 15,000 pregnant women in 
each cohort
Incidence rate in 
unvaccinated 
cohortOne-sided t ype I nominal 
errorTrue relative 
riskPower Beta
1% 0.625 % 1.25 95.7% 4.3%
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a33 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 347. STUDY CONSIDERA TIONS
Most of the Boostrix exposures during pregnancy  will occur at 27 weeks gestation or 
later. As such, we expect pregnancy  outcomes that occur earlier in pregnancy  such as 
spontaneous abortion and therapeutic abortion to be rare in our stud y. Furthermore, while 
we will describe the frequency  of congenital anomal iesamong the exposed and 
unexposed cohorts, we note that the most plausible time period for development of 
congenital anomalies is during earl y pregnancy (35). Cautious interpretation of maternal 
Boostrix immunization and congenital anomal iesis warranted.
One potential limitation is that the exposed (Boostrix vaccinated) cohort and the 
unexposed coh ort come from different time periods. With the exposed cohort from the 
ICD-10 era and the unexposed cohort from the ICD-9 era there is a potential risk of bias 
if the prevalence of adverse events is higher or lower in either exposed or unexposed 
cohorts due to coding variation or secular trends .This issue is not specific to KPSC but 
rather affects all health care organizations and similar research conducted in the U.S . 
However, 
this is not a major concern at KPSC as there is specific mapping (crosswalk) 
between ICD-9 and ICD -10 for all of the outcomes (36, 37) . Most importantly , no matt er 
which sy stem is used, a comprehensive list of codes will be used to identify  all potential 
events of interest. In addition ,
areview of medical records will be conducted to determine 
whether the events are truly  incident events with onset after the inde x date (vaccination 
date for the exposed). Similarly , by using a historical cohort to identify  the unexposed 
group to compare to a current exposed cohort , there is a concern that the baseline 
incidence of the selected safet y endpoints will vary significantl y between the Tdap 
(Boostrix) vaccination period and the historical comparison period . However, the 
advantage of comparing to a historical population of pregnant women during 
approx imately  2012- 2013 is that we are identify ing an unvaccinated group during a 
period when prenatal Tdap vaccine uptake was low, making these pregnant women more 
representative of an unvaccinated cohort. A current unvaccinated cohort would yield a 
small and selective sample (given over 70% Tdap uptake) that is not representative of an 
unvaccinated group and would be affected b y confounding b y indication. 
If a safet y signal is identified, further exploration of the data will be completed to 
investigate alterna tivepotential sources for the Boostrix -outcome association
, including
but not limited to changing secular trends or coding practices. 
8. CONDUCT OF THE STUDY
GlaxoSmithKline (GSK) will engage KPSC to provide activities including conducting the 
study  on behalf of GSK. The study  will be conducted by  the Investigator at KPSC‚Äôs 
premises under the oversight of the sponsor, GSK. Through this partnership, we will 
provide critical information about the safet y ofmaternal vaccination with Boostrix in a 
community  setting.
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a34 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 358.1. Regulatory  and ethical considerations
The study  will be conducted in accordance with all applicable regulatory  requirements, 
including all applicable su bject privacy  requirements and the guiding principles of the 
Declaration of Helsinki , International Ethical Guidelines for Epidemiological Studies 
(CIOMS), FDA Best Practices for Conducting and Reporting Pharmacoepidemiologic 
Safety  Studies using Electroni c Healthcare Data, and I SPE guidelines for Good 
Pharmacovigilance Practice (GPP).
The KPSC team will obtain approval of the final protocol from the Institutional Review 
Board (IRB) at KPSC prior to study  start.
8.2. Informed consent and data privacy
Subjects included in this study  will be identified a mong KPSC health plan members. 
Informed consent is not required because Boostrix is a licensed vaccine given to eligible 
KPSC members as part of routine clinical care. KPSC will obtain I RB approval for the 
use of patient data and to ensure protection of data privacy . Individual w ritten Health 
Insurance Portability  and Accountability  Act ( HIPAA )authorizations prior to initiating 
data collection will not be required .
8.3. Additional data
Additional summary  level data wi ll be provided from KPSC to GSK throughout the 
course of the stud y. This will include aggregated data from automated data sources, and 
will include the following:
ÔÇ∑Monthly  vaccine uptake report including uptake among pregnant women and non -
pregnant individu als. Uptake among pregnant women will be broken down by  
women vaccinated at 27 weeks and above versus women vaccinated before 27 
weeks. 
ÔÇ∑Quarterl y cohort identification report, i.e., exposure data: This report will provide the 
uptake among pregnant women v accinated on or after the 1stday of th e 27thweek of 
gestation, with additional inclusion/exclusion criteria applied as indicated in the 
study  protocol.
ÔÇ∑Quarterl y identification of pre -specified adverse events and pregnancy  outcomes.
ÔÇ∑Quarterl y report demonstrating the progress of chart review for the pre -specified 
adverse events (e.g. number of events identified, number in progress of being 
reviewed, number completed) .
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a35 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 369. REFERENCES
1. Munoz FM, Eckert LO, Katz MA, L ambach P, Ortiz JR, Bauwens J, et al. Key  
terms for the assessment of the safet y of vaccines in pregnancy : Results of a 
global consultative process to initiate harmonization of adverse event definitions. 
Vaccine. 2015;33(47):6441-52.
2. Centers for Disease Control and Prevention (CDC) 2018; Accessed  
https://www.cdc.gov/features/pregnancy -infant -loss-day/index.html on November 
2, 2018.
3. Mattoo S, Cherry  JD. Molecular pathogenesis, epidemiology , and clinical 
manifestations of respiratory  infections due to Bordetella pertussis and other 
Bordetella subspecies. Clin Microbiol Rev. 2005;18(2):326-82.
4. Koepke R, Eickhoff JC, Ay ele RA, Petit AB, Schauer SL, Hopfensperger DJ, et 
al. Estimating the effectiveness of tetanus -diphtheria- acellular pertussis vaccine 
(Tdap) for preventing pertussis: evidence of rapidly  waning immunity  and 
difference in effectiveness by  Tdap brand. J I nfect Dis. 2014;210(6):942 -53.
5. Klein NP, Bartlett J, Fireman B, Baxter R. Waning Tdap Effectiveness in 
Adolescents. Pediatrics. 2016;137(3):e20153326.
6. T artof SY, Lewis M, Keny on C, White K, Osborn A, L iko J, et al. Waning 
immunity  to pertussis following 5 doses of DTaP. Pediatrics. 2013;131(4):e1047 -
52.
7. Broder KR, Cortese MM, I skander JK, Kretsinger K, Slade BA, Brown KH, et al. 
Preventing tetanus, dip htheria, and pertussis among adolescents: use of tetanus 
toxoid, reduced diphtheria toxoid and acellular pertussis vaccines 
recommendations of the Advisory  Committee on Immunization Practices (ACI P). 
MMWR Recomm Rep. 2006;55(RR- 3):1-34.
8. California Depar tment of Public Health 2010; Accessed 
http://www.eziz.org/PDF/CDPH%20Pertussis%20Immunization%20Policy%20Ju
ly%202010.pdf on October 31, 2017.
9. CDC. Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria 
Toxoid and Acellular Pertussis (Tdap ) Vaccine from the Advisory  Committee on 
Immunization Practices, 2010. Morb Mortal Wkly Rep;60 (01):13-5.
10. CDC Advisory  Committee for I mmunization Practices Recommends Tdap 
Immunization for Pregnant Women 2012; Accessed 
http://www.cdc.gov/media/releases /2012/a1024_Tdap_immunization.html on 
November 8, 2017.
11.
GlaxoSmithKline Biologicals; Accessed at Food and Drug Administration at 
http://www.fda.gov/downloads/BiologicsBloodVaccines/UCM152842.pdf on 
September, 22, 2017.
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a36 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 3712. Munoz FM, Bond NH, Maccato M, Pinell P, Hammill HA, Swamy  GK, et al. 
Safety  and immunogenicity  of tetanus diphtheria and acellular pertussis (Tdap) 
immunization during pregnancy  in mothers and infants: a randomized clinical 
trial. JAMA. 2014;311(17):1760-9.
13. Zhetey eva YA, Moro PL, Tepper NK, Rasmussen SA, Barash FE, Revzina NV, et 
al. Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and 
acellular pertussis vaccines in pregnant women. Am J Obstet Gy necol. 
2012;207(1):59.e1-7.
14. Berenson AB, Hirth JM, Rahman M, Laz TH, Rupp RE, Sarpong KO. Maternal 
and infant outcomes among women vaccinated against pertussis during 
pregnancy . Hum Vaccin Immunother. 2016;12(8):1965 -71.
15. Kharbanda EO, Vazquez -Benitez G, Lipkind HS, Klein NP, Cheetham TC, 
Naleway  A, et al. Evalu ation of the association of maternal pertussis vaccination 
with obstetric events and birth outcomes. JAMA. 2014;312(18):1897 -904.
16. DeSilva M, Vazquez -Benitez G, Nordin JD, Lipkind HS, Klein NP, Cheetham 
TC, et al. Maternal Tdap vaccination and risk of i nfant morbidity . Vaccine. 
2017;35(29):3655 -60.
17. Layton JB, Butler AM, Li D, Boggess KA, Weber DJ, McGrath L J, et al. Prenatal 
Tdap immunization and risk of maternal and newborn adverse events. Vaccine. 
2017;35(33):4072 -8.
18. Kharbanda EO, Vazquez -Benit ez G, Lipkind HS, Klein NP, Cheetham TC, 
Naleway  AL, et al. Maternal Tdap vaccination: Coverage and acute safet y 
outcomes in the vaccine safet y datalink, 2007 -2013. Vaccine. 2016;34(7):968-73.
19. DeSilva M, Vazquez -Benitez G, Nordin JD, L ipkind HS, Romitt i PA, DeStefano 
F, et al. Tdap Vaccination During Pregnancy  and Microcephaly  and Other 
Structural Birth Defects in Offspring. Jama. 2016;316(17):1823 -5.
20. Koebnick C, Langer -Gould AM, Gould MK, Chao CR, Iy er RL, Smith N, et al. 
Sociodemographic character istics of members of a large, integrated health care 
system: comparison with US Census Bureau data. Perm J. 2012;16(3):37 -41.
21. American College of Obstetricians and Gy necologists. Methods for estimating the 
due date. Committee Opinion No. 700. Obstet Gy necol. 2017;129:e150 -4.
22. Eunice Kenned y Shriver National Institute of Child Health and Human 
Development 2017; Accessed https://www.nichd.nih.gov/health/topics/high -
risk/conditioninfo/pages/factors.aspx on October 30, 2017.
23. American College of Obste tricians and Gy necologists. Premature rupture of 
membranes. Practice Bulletin No. 172. Obstet Gynecol. 2016;128(4):e165 -77.
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a37 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 3824. American College of Obstetricians and Gy necologists. Executive summary : 
hypertension in pregnancy . Obstet Gy necol. 2013;122:1122-31.
25. American College of Obstetricians and Gynecologists. Intrapartum management 
of intraamniotic infection. Committee Opinion No. 712. Obstet Gy necol. 
2017;130:e95-101.
26. American College of Obstetricians and Gy necologists. Management of preterm 
lab
or. Practice Bulletin No. 171. Obstet Gy necol. 2016;128:e155 -64.
27. American College of Obstetricians and Gy necologists. Fetal growth restriction. 
Practice Bulletin No. 134. Obstet Gy necol. 2013;121:1122-33.
28. American College of Obstetricians and Gy necologists. Practice Bulletin No. 183: 
Postpartum Hemorrhage. Obstet Gy necol. 2017;130(4):e168- e86.
29. American College of Obstetricians and Gy necologists. ACOG Practice Bulletin 
No. 102: management of stillbirth. Obstet Gy necol. 2009;113(3):748 -61.
30. Ame rican College of Obstetricians and Gy necologists. ACOG Practice Bulletin 
No. 135: Second- trimester abortion. Obstet Gy necol. 2013;121(6):1394 -406.
31. American College of Obstetricians and Gy necologists. The American College of 
Obstetricians and Gy necologi sts Practice Bulletin no. 150. Earl y pregnancy loss. 
Obstet Gy necol. 2015;125(5):1258 -67.
32. Harris PA, Tay lor R, Thielke R, Pay ne J, Gonzalez N, Conde JG. Research 
electronic data capture (REDCap) --a metadata -driven methodology  and workflow 
process for providing translational research informatics support. J Biomed I nform. 
2009;42(2):377 -81.
33. National Birth Defects Prevention Network 2018; Accessed 
https://www.nbdpn.org/icd10.php on November 1, 2018.
34. Zou G. A modified poisson regression approach to prospective studies with binary  
data. Am J Epidemiol. 2004;159(7):702-6.
35. DeSilva M, Munoz FM, McMillan M, Kawai AT, Marshall H, Macartney  KK, et 
al. Congenital anomalies: Case definition and guidelines for data collection, 
analysis, and presentation of immunization safety data. Vaccine. 
2016;34(49):6015 -26.
36. ICD10Data.com 2017; Accessed http://www.icd10data.com/.
37. Centers for Medicare & Medicaid Services 2017; Accessed 
https://www.cms.gov/Medicare/Coding/I CD10/2017 -ICD-10- CM-and-
GEMs.html on October 30, 2017.
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a38 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 39APPENDIX A AMENDMENTS A ND A DMINISTRA TIVE 
CHA NGES TO THE PROTOCOL
GlaxoSmithKline Biologicals SA
Vaccines R & D
Protocol Amendment 2
eTrack study number 
and Abbreviated Title207221 (EPI-PERTUSSIS -047 VS US DB)
Amendment number: Amendment 2
Amendment date: Final: 12 November 2019
Rationale/background for changes: 
The protocol has been amended to modify the secondary endpoint of ‚Äúpost -
partum hemorrhage (PPH)‚Äù to ‚Äútransfusion during delivery hospitalization‚Äù as 
a proxy for severe PPH. We originally planned to identify PPH from automated 
diagnosis codes (ICD -9 and ICD -10) and then perform chart review to confirm 
the event. However, in October 2017 (ACOG Practice Bulletin PPH 2017), the 
threshold for estimated blood loss (EBL) for PPH diagnosis changed, affecting 
the comparison between the historical (~2012- 2013) and th e Boostrix exposed 
(2018 -2019) cohorts. The potential for using EBL as an objective measure is 
limited by differential missingness of EBL data between these two cohorts as well 
as inconsistency in EBL measurements. We propose to use transfusion during 
delivery hospitalization as an indicator of severe blood loss and as a proxy for 
severe PPH. Transfusion can be captured by procedure codes, and transfusion 
data are stable across the study period. Transfusion is a relevant endpoint 
because hemorrhage that lea ds to blood transfusion is the leading cause of severe 
maternal morbidity in the United States (ACOG Practice Bulletin PPH 2017).
The following changes have been implemented .
ÔÇ∑Secondary objectives; Data collection Figure 1; Statistical methods Tables 6 
and 7 -"Post -partum hemorrhage" was changed to " Transfusion during 
delivery hospitalization."
ÔÇ∑Case definitions; Data collection and management -Transfusion during 
delivery hospitalization is captured by procedure codes and will not be chart 
reviewed. 
ÔÇ∑Data collection Figure 1; Statistical methods Table 7 - Transfusion will be 
identified among pregnant women with delivery hospitalizations.
ÔÇ∑Analysis of primary and secondary objectives; Statistical methods Table 7 -
The statistical method for analyzing transfusi on will be an adjusted Poisson 
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a39 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 40regression model. Robust variance estimation is not planned since the 
incidence is expected to be <2%.
Amended text has been included in bold italics and deleted text in strikethrough in the 
following sections:
Synopsis:
Secondary Objectives ÔÇ∑Post-partum hemorrhage Transfusion during delivery 
hospitalization (as a proxy for severe post -partum 
hemorrhage)
Endpoint(s) Secondary
ÔÇ∑Post-partum hemorrhage Transfusion during delivery 
hospitalization
With the exception of SGA, andpreterm delivery ,and 
transfusion , medical records of the potential events will then 
be reviewed b y trained research associates to confirm the 
diagnosis and to ascertain that it is an incident event.
Section 2.2 Secondary objectives
ÔÇ∑ Post-partum hemorrhage Transfusion during delivery hospitalization (as a proxy for 
severe post -partum hemorrhage)
Section 4.2 Case definitions
With the exception of SGA, and preterm delivery ,and transfusion, chart review will be 
performed for the pre -specified matern al and infant adverse events to confirm the events 
and that the events are incident after the index date.
Section 5 Data collection and management
We will rely  on automated data from the EHR to ascertain SGA , and preterm delivery , 
and transfusion .
Figure 1. Illustration of data flow was updated and changes include:
ÔÇ∑Post-partum hemorrhage secondary  endpoint was changed to ‚ÄúTransfusion during 
delivery  hospitalization ‚Äù
ÔÇ∑Modified sentence ‚ÄúAll secondary  endpoints but transfusion will be confirmed by 
medical record review‚Äù
ÔÇ∑Secondary  endpoints, footnote a, modified to say  ‚ÄúIdentified among pregnant women 
with KPSC delivery delivery hospitalization ‚Äù
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a40 12-NOV-2019
CONFIDENTIA L
207221 (EPI-PERTUSSIS -047 VS US DB )
Protocol Amendment 2 Final
12-NOV -2019 41Section 6.1 Primary and secondary pre -specified events of interest 
Table 6 List of primary  and secondary  endpoints
Secondary 
endpointsPost-partum hemorrhage Transfusion during delivery hospitalization 
Poor fetal growth
Stillbirth/fetal death with or without congenital anomalies
Neonatal death (within 28 days of birth)
Maternal death (while pregnant or within 42 days of end of pregnancy)
Placental abruption
Preterm pre -labor rupture of membranes (PPROM)
Congenital anomalies at birth and through 6 months of age
Spontaneous abortion with or without congenital anomalies (only for women exposed to 
Boostrix before the 27thweek of gestation)
Therapeutic abortion with or without congenital anomalies (only for women exposed to 
Boostrix before the 27thweek of gestation)
Section 6.2.2 Analysis of primary and secondary objectives
For events identified at delivery  such as SGA , and preterm delivery , and transfusion 
during delivery hospitalization ,we will calculate crude incidence and 95% confidence 
intervals (CI) for each adverse event for the exposed and unexposed groups.
Table 7 Analytic population and statistical methods by  endpoint
Secondary endpoints Analytic population Statistical Methods
Post-partum hemorrhage Transfusion 
during delivery hospitalizationPregnant women with KPSC
delivery delivery hospitalizationAdjusted Poisson regression model , 
with robust variance estimate
 
CONFIDENTIAL
207221 (EPI-PERTUSSIS-047 VS US DB)
Protocol Amendment 2 Final
05cc3b67a9ba431ae514559e26df5e5186fbe84a41 12-NOV-2019